tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dynavax raises 2025 Heplisav-B net product revenue view to $315M-$325M

Previous guidance was $305M-$325M. Consensus for 2025 revenue is $330.56M. Sees 2025 adjusted EBITDA at least $75M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1